We have paradigmatic advances though. CAR-T cell therapy is going to change a lot of things, and it's just around the corner.
Heck, you don't even have to get into cutting edge cell therapy to find interesting things. Bispecific antibodies are around the corner as well. Heck, even small molecules are getting very interesting lately, with some compounds being able to fullfill several roles (EG: ruxolitinib was born as a JAK2 inhibitor, in principle to treat JAK2-positive MPNs. Only, as it turns out, it also affects JAK2 negative MPNs because all MPNs have the JAK pathway upregulated. On top of that it has a big impact on circulating cytokines, giving it interesting immunomodulatory properties that give it value in some autoimmune disorders, as well as management of GvHD)
You're kind of obsessively paranoid with that you know? It's not like cancer diagnosis is something decided on one single test.
And yet...
I'm not saying this stuff out of fear. I'm saying it out of frustration.
First, the source of that study is about thyroid cancer overdiagnosis, not false diagnosis
Second: eh, even "overdiagnosis" is likely simplifying the matter too much, and does not necessarily mean it's wrong to at the very least keep track of these patients.
I found this interesting:
http://www.medscape.com/viewarticle/834450?pa=uGWUPu%2F0P%2BqBvC5BjtUnZXa6zDoDuCDftSexA3OoKz9feeMGfy8aq88yGPhQ7X8oJyGvMX%2Fu%2BWdIXoARf%2FT0zw%3D%3D
Dr Grogan also believes that "the term 'overdiagnosis' is being used incorrectly by this group."
Thyroid cancer has such a high 5-year overall survival rate (about 97%) that it cannot be expected that mortality will significantly increase as incidence climbs, he explained. "A concomitant mortality increase would be expected for, say, pancreatic cancer, but not thyroid cancer," he said. Thus, if a hallmark of overdiagnosis cannot be expected to be seen, then the term is not fitting, he suggested.
Dr Grogan believes that the paper's public health perspective is a limitation for clinicians. "The big question is: Do these patients need surgery?" he said. "The answer can't be that you do nothing."
At the same time, Dr Grogan advocates for clinical trials that explore other management options for patients with thyroid cancer.
Thyroid cancer is a candidate for active surveillance, but protocols are needed and must be investigated. Currently, researchers in Japan are "leading the way" with related prospective studies, he said.
It's a very tough call to make TBH. Some years ago there were talks as well about "watch and wait" attitudes with prostate cancer, instead of treating all of them, because "the impact on mortality was little". Except... as it turns out, that's simplifying things a bit too much as well. Namely, it was shown that while survival rates were similar, bone methases were far less frequent in the treatment groups than in the treatment ones. And they had a huge impact on quality of life. Heck, even the "no impact on survival" was not completely true either. Part of it was because it's diagnosed in older people and it's sluggish... but people *are* living longer now, and there is an impact in survival as well.